ASGCT is excited to host a thought-provoking conversation, moderated by Jodi Wolff, PhD, to further deconstruct issues of responsibility and obligation in the post-approval gene therapy landscape.
This fireside chat will address topics related to data capture for long-term monitoring for durability and safety, standardization to enable comparability to facilitate/identify next-generation therapies, and tensions that exist in the evolving landscape.
Speakers and Panelists
-
, Chief Operating Officer at (FAST)
-
Andrew McFadyen, Ethics Lead - Precision Child Health at
-
John Knighton, Vice President, API Cell & Gene Development